Skip to main content
Journal of Patient-Reported Outcomes

Table 6 Interscale correlations of EORCT QLQ-BN20

From: Translation and validation of the Urdu version of the European organization for research and treatment of cancer core quality of life questionnaire (EORTC QLQ-C30) and brain module (QLQ-BN20) in primary brain tumor patients

 

FU

VD

M

CD

HA

SZ

DS

HL

IS

WL

BC

FU

1

0.402*

0.458*

0.346*

0.280*

0.346*

0.628*

0.245*

0.109

0.385*

0.358*

VD

0.402*

1

0.372*

0.467*

0.202*

0.167*

0.441*

0.216*

0.077

0.256*

0.288*

MD

0.458*

0.372*

1

0.568*

0.183*

0.191*

0.605*

0.203*

0.137+

0.683*

0.400*

CD

0.346*

0.467*

0.568*

1

0.092

0.141+

0.450*

0.046

0.235*

0.366*

0.187*

HA

0.280*

0.202*

0.183*

0.092

1

0.085

0.259*

0.134+

0.057

0.153+

(0.258*

SZ

0.346*

0.167*

0.191*

0.141+

0.085

1

0.254*

 − 0.052

 − 0.083

0.278*

0.024

DS

0.628*

0.441*

0.605*

0.450*

0.259*

0.254*

1

0.221*

0.176*

0.453*

0.348*

HL

0.245*

0.216*

0.203*

0.046

0.134

 − 0.052

0.221*

1

0.325*

0.128+

0.485*

IS

0.109*

0.077

0.137+

0.235*

0.057

 − 0.083

0.176*

0.176*

1

0.149+

0.242*

WL

0.385*

0.256*

0.683*

0.366*

0.153+

0.278*

0.453*

0.453*

0.149+

1

0.350*

BC

0.358*

0.288*

0.400*

0.187*

0.258*

0.024

0.348*

0.348*

0.242*

0.350*

1

  1. FU, future uncertainty; VD, visual disorder; M, motor dysfunction; CD, communication deficit; HA, headache; SZ, seizures; DS, drowsiness; HL, hair loss; IS, itchy skin; WL, weakness in leg; BC, bladder control
  2. +Significant at p < 0.05
  3. *Significant at p < 0.01
Back to article page